These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 18814087)

  • 1. [Novel concepts in the pathobiology of pulmonary arterial hypertension].
    Rosenkranz S
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S167-9. PubMed ID: 18814087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular and molecular pathobiology of pulmonary arterial hypertension.
    Humbert M; Morrell NW; Archer SL; Stenmark KR; MacLean MR; Lang IM; Christman BW; Weir EK; Eickelberg O; Voelkel NF; Rabinovitch M
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):13S-24S. PubMed ID: 15194174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Update in basic research in the therapy of pulmonary arterial hypertension].
    Schermuly R; Grimminger F
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S170-2. PubMed ID: 18814088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Guignabert C; Günther S; Girerd B; Jaïs X; Algalarrondo V; Price LC; Savale L; Sitbon O; Simonneau G; Humbert M
    Pharmacol Ther; 2014 Feb; 141(2):172-91. PubMed ID: 24134901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Update: Current clinical developments in pulmonary hypertension].
    Dumitrescu D; Ghofrani HA; Grimminger F; Hoeper MM; Rosenkranz S
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S160-3. PubMed ID: 19718605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure.
    Ray L; Mathieu M; Jespers P; Hadad I; Mahmoudabady M; Pensis A; Motte S; Peters IR; Naeije R; McEntee K
    Exp Physiol; 2008 Mar; 93(3):434-42. PubMed ID: 17993509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
    Klein M; Schermuly RT; Ellinghaus P; Milting H; Riedl B; Nikolova S; Pullamsetti SS; Weissmann N; Dony E; Savai R; Ghofrani HA; Grimminger F; Busch AE; Schäfer S
    Circulation; 2008 Nov; 118(20):2081-90. PubMed ID: 18955668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapeutics and practical management strategies for pulmonary arterial hypertension.
    Agarwal R; Gomberg-Maitland M
    Am Heart J; 2011 Aug; 162(2):201-13. PubMed ID: 21835279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The etiopathogenesis of pulmonary hypertension: inflammation, vascular remodeling].
    Kayikçioğlu M
    Anadolu Kardiyol Derg; 2010 Aug; 10 Suppl 1():5-8. PubMed ID: 20819761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension.
    Berghausen E; ten Freyhaus H; Rosenkranz S
    Handb Exp Pharmacol; 2013; 218():381-408. PubMed ID: 24092349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current insights on the pathogenesis of pulmonary arterial hypertension.
    Perros F; Dorfmüller P; Humbert M
    Semin Respir Crit Care Med; 2005 Aug; 26(4):355-64. PubMed ID: 16121311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of PDGF signaling in cigarette smoke-induced pulmonary arterial hypertension in rat.
    Xing AP; Hu XY; Shi YW; Du YC
    Inhal Toxicol; 2012 Jul; 24(8):468-75. PubMed ID: 22746397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary arterial hypertension: pathobiology, diagnosis and treatment.
    Golpon HA; Welte T; Hoeper MM
    Minerva Med; 2005 Aug; 96(4):303-14. PubMed ID: 16179896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel approaches to the pharmacotherapy of pulmonary arterial hypertension.
    Olsson KM; Hoeper MM
    Drug Discov Today; 2009 Mar; 14(5-6):284-90. PubMed ID: 19121410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective.
    Gomberg-Maitland M; Dufton C; Oudiz RJ; Benza RL
    J Am Coll Cardiol; 2011 Mar; 57(9):1053-61. PubMed ID: 21349396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dana Point: what is new in the treatment of pulmonary hypertension?].
    Hoeper MM; Ghofrani HA; Grimminger F; Rosenkranz S
    Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S191-5. PubMed ID: 18814094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapies for the treatment of pulmonary hypertension.
    Stenmark KR; Rabinovitch M
    Pediatr Crit Care Med; 2010 Mar; 11(2 Suppl):S85-90. PubMed ID: 20216170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of experimental pulmonary hypertension by PDGF inhibition.
    Schermuly RT; Dony E; Ghofrani HA; Pullamsetti S; Savai R; Roth M; Sydykov A; Lai YJ; Weissmann N; Seeger W; Grimminger F
    J Clin Invest; 2005 Oct; 115(10):2811-21. PubMed ID: 16200212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension.
    Dumas de la Roque E; Savineau JP; Bonnet S
    Pharmacol Ther; 2010 May; 126(2):186-99. PubMed ID: 20206649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities.
    Sakao S; Tatsumi K
    Int J Cardiol; 2011 Feb; 147(1):4-12. PubMed ID: 20692712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.